BiotechTube

Tominersen + Placebo

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Huntington Disease

Conditions

Huntington Disease

Trial Timeline

Feb 3, 2023 → Apr 1, 2027

NCT ID
NCT05686551

About Tominersen + Placebo

Tominersen + Placebo is a phase 2 stage product being developed by Roche for Huntington Disease. The current trial status is active. This product is registered under clinical trial identifier NCT05686551. Target conditions include Huntington Disease.

What happened to similar drugs?

1 of 11 similar drugs in Huntington Disease were approved

Approved (1) Terminated (2) Active (8)
✅TetrabenazineLundbeckApproved
🔄Votoplam (blinded) + PlaceboNovartisPhase 3
🔄RO7234292 (RG6042)RochePhase 3
🔄RO7234292 + PlaceboRochePhase 3
🔄DimebonPfizerPhase 3
❌Dimebon (latrepirdine)PfizerPhase 3
🔄RiluzoleSanofiPhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05686551Phase 2Active

Competing Products

20 competing products in Huntington Disease

See all competitors
ProductCompanyStageHype Score
atomoxetine + Matching PlaceboEli LillyPhase 2
35
Votoplam (blinded) + PlaceboNovartisPhase 3
47
VotoplamNovartisPhase 2
39
Branaplam + PlaceboNovartisPhase 2
27
AFQ056 + PlaceboNovartisPhase 2
27
RO7234292 (RG6042)RochePhase 1
29
RO7234292 (RG6042)RochePhase 3
40
RO7234292 (RG6042)RochePhase 2
35
RG6496 + PlaceboRochePhase 1
36
RO7234292 + PlaceboRochePhase 3
40
PF-02545920 + PF-02545920PfizerPhase 2
35
Dextromethorphan + Dimebon + DextromethorphanPfizerPhase 1
29
DimebonPfizerPhase 3
40
Dimebon (latrepirdine)PfizerPhase 3
32
20 mg BID of PF-02545920PfizerPhase 2
27
PF-02545920 + Placebo + PF-02545920 + PlaceboPfizerPhase 2
35
RiluzoleSanofiPhase 3
40
ALN-HTT02 + PlaceboAlnylam PharmaceuticalsPhase 1
33
TetrabenazineLundbeckApproved
36
ValbenazineNeurocrine BiosciencesPhase 3
41